Skip to main content
. 2020 Sep 2;10(24):11063–11079. doi: 10.7150/thno.45674

Figure 7.

Figure 7

CSRP2 regulates Hippo, ERK, and PAK signaling pathways to suppresses CRC cell invasion and EMT via Rac1. (A) Rac1 activation was detected by WB in CSRP2- depleted CRC cells and control cells treated with Rac1 inhibitor NSC23766. (B) WB was performed to detect the activation of LATS1, YAP in Hippo signal pathways and the activation of ERK in ERK signal pathways, and the changes of EMT markers. (C) The expression of E-cadherin and vimentin were analyzed by IF. (D) WB was performed to detect the activation of PAK, LIMK and cortactin in the skeleton signal pathway. (E) Phalloidin IF staining analyzes the pseudopodia. (F) The changes of pseudopodia were detected by scanning electron microscope. (G) Transwell invasion assay was used to analyze the changes of invasive ability of cells; (H) Schematic diagram showing the mechanism of action of CSRP2 in CRC. CSRP2 could inhibit the activation of Rac1 by inhibiting the p-p130cas, thus promoting the activation of the Hippo pathway, and simultaneously inhibiting the PAK-LIMK-cortactin and ERK signal pathway, thereby inhibiting the EMT and metastasis of CRC.